Metagenomi, Inc. (NASDAQ:MGX) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its position in Metagenomi, Inc. (NASDAQ:MGXFree Report) by 130.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,799 shares of the company’s stock after acquiring an additional 7,256 shares during the quarter. BNP Paribas Financial Markets’ holdings in Metagenomi were worth $28,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Rhumbline Advisers acquired a new position in Metagenomi during the 2nd quarter worth $26,000. Resolute Advisors LLC lifted its stake in Metagenomi by 165.0% in the second quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock worth $108,000 after acquiring an additional 16,500 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Metagenomi in the 2nd quarter valued at approximately $66,000. Novo Holdings A S raised its holdings in shares of Metagenomi by 3.5% in the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock valued at $7,344,000 after purchasing an additional 60,825 shares in the last quarter. Finally, Green Alpha Advisors LLC acquired a new position in shares of Metagenomi during the third quarter worth $69,000.

Metagenomi Stock Performance

NASDAQ MGX opened at $4.05 on Friday. The firm’s fifty day moving average is $2.31 and its two-hundred day moving average is $3.18. Metagenomi, Inc. has a one year low of $1.61 and a one year high of $12.74.

Analyst Ratings Changes

A number of brokerages have issued reports on MGX. HC Wainwright lifted their price target on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th. Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of Metagenomi in a research report on Wednesday, November 20th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Metagenomi has an average rating of “Moderate Buy” and an average target price of $16.67.

Get Our Latest Stock Report on Metagenomi

About Metagenomi

(Free Report)

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

Featured Articles

Want to see what other hedge funds are holding MGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metagenomi, Inc. (NASDAQ:MGXFree Report).

Institutional Ownership by Quarter for Metagenomi (NASDAQ:MGX)

Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.